We often see claims from the USA that Synthroid, "the brand name", is substantially better at treating hypothyroid patients than generic levothyroxine (GL).
This paper claims to demonstrate this is true. And that, despite the higher cost of Synthroid, its use results in lower overall medical costs.
But, even within the paper, it admits:
Our study examined GL utilization as a single cohort and did not differentiate between different generics, whose effectiveness may not be identical.
That implies some of the patients might have had different products, and different combinations of products, dispensed at each refill. We often discuss the non-interchangeability of levothyroxine products. It sets up the study to fall into Simpson's Paradox.
It ends up claiming, in effect, that no generic could ever be as good as Synthroid. Yet the paper fails to prove that at any level.
The paper is based on getting TSH into reference interval and costs of illnesses. No mention of well-being.
My view is that the paper exists ONLY to persuade those who foot the bills that despite the higher cost of Synthroid, they will save money overall.
I suspect you could have chosen almost any of the generic levothyroxine products as the reference product and achieved similar-seeming results. However, until properly researched, treat that as a guess based on cynicism.
Adv Ther. 2021 Dec 14.
doi: 10.1007/s12325-021-01969-3. Online ahead of print.
Comparative Effectiveness of Persistent Use of a Name-Brand Levothyroxine (Synthroid®) vs. Persistent Use of Generic Levothyroxine on TSH Goal Achievement: A Retrospective Study Among Patients with Hypothyroidism in a Managed Care Setting
Liya Wang 1 , Yaozhu J Chen 2 , Michael Grabner 3 , Bal Nepal 1 , Amit Bodhani 2 , Ramon Espaillat 2 , James V Hennessey 4
Affiliations
• 1 HealthCore, Inc, 123 Justison Street, Suite 200, Wilmington, DE, 19801, USA.
• 2 AbbVie, North Chicago, IL, USA.
• 3 HealthCore, Inc, 123 Justison Street, Suite 200, Wilmington, DE, 19801, USA. mgrabner@healthcore.com.
• 4 Beth Israel Deaconness Medical Center, Boston, MA, USA.
• PMID: 34905150
• DOI: 10.1007/s12325-021-01969-3
Abstract
Introduction: Levothyroxine monotherapy (Synthroid® or multiple generic levothyroxine [GL] formulations) is standard treatment for hypothyroidism. Our objective was to compare effectiveness (as measured by achievement of thyroid-stimulating hormone [TSH] levels) and economic outcomes of Synthroid vs. any one of multiple GLs in patients with hypothyroidism.
Methods: Data for this retrospective cohort study were obtained from the HealthCore Integrated Research Database®. All study patients had ≥ 2 claims between 1 January 2006 and 31 December 2017 with ICD-9/10-CM diagnosis codes for hypothyroidism; were persistent users of Synthroid vs. any GL; and had ≥ 1 TSH laboratory result during 12-month follow-up. Patients were divided into one of two cohorts based on index medication and were 1:1 matched using propensity scores. The primary outcome was the proportion of patients with last TSH laboratory result during follow-up within the reference range (0.3-4.12 mIU/L). Secondary outcomes included all-cause and hypothyroidism-related healthcare resource utilization (HCRU) and costs.
Results: After propensity score matching, the Synthroid and GL cohorts each contained 18,382 patients. At follow-up, significantly more patients receiving Synthroid were in the TSH reference range vs. GL (78.5% vs. 77.2%, respectively, p = 0.002). HCRU and costs were broadly similar between the cohorts in terms of all-cause inpatient hospitalizations, emergency department visits, outpatient services, and pharmacy fills. Irrespective of index medication, patients with TSH within the reference range had significantly lower hypothyroidism-related medical and total costs compared to those outside the range.
Conclusions: This real-world data study showed Synthroid was associated with better TSH target achievement vs. GL in a US managed care population. Achieving TSH goals may provide substantial economic value by reducing hypothyroidism-related HCRU and costs.
Keywords: Comparative effectiveness; Hypothyroidism; Levothyroxine; TSH.
pubmed.ncbi.nlm.nih.gov/349...
Full paper freely accessible here:
link.springer.com/article/1...
If you are wondering why this paper is open access when so many are not, I suggest you read this statement from the paper:
Funding
Study funding was provided by AbbVie, Inc., to HealthCore, Inc. The study sponsor is also funding the journal’s Rapid Service and Open Access Fees.